Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

Citi analysts forecast 19% earnings growth for the healthcare sector in 2025 amid improving fundamentals and a boom in weight ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Emily Field, Barclays head of European pharmaceutical research, joins 'Squawk Box' to discuss the state of the weight loss drug market, disappointing trial results of Novo Nordisk's experimental ...

The latest health news includes WuXi's sale of its Advanced Therapies unit due to US restrictions, expanding famine in Sudan ...

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...

Zealand Pharma's GLP-2 drug candidate fails to gain FDA approval due to request for additional trial to confirm efficacy and safety.

Seemingly overnight, millions of people were taking the medicines, known as GLP-1s, while blockbuster drugs like Ozempic, Wegovy, Mounjaro, and Zepbound brought in billions for pharma companies, and a ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

Taxi jumps curb, slams into Christmas Day crowd outside Manhattan Macy’s on W. 34th St. A taxi cab jumped the curb and slammed into six pedestrians walking near Macy's on W. 34th St. and Sixth ...